Amidoxime functionalized chitosan for uranium sequestration in vivo.

Amidoxime functionalized chitosan (AC) was recommended as a chelator for uranium sequestration in vivo in this study, and the structure-activity relationship was also explored. Compared with ZnNa-DTPA, which was a commercial uranium mobilization drug, AC exhibited excellent biocompatibility and uranium removal efficiency, whether by injection or orally, which could reduce the amounts of uranium deposited in kidneys and femurs by up to 43.6% and 32.3%. In particular, ACs still possessed the ability to mobilize uranium in vivo even if administration was delayed for 72 h.